Finepoint Capital LP Acadia Pharmaceuticals Inc Transaction History

Finepoint Capital LP

$347 Million
Q2 2024

A detailed history of Finepoint Capital LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Finepoint Capital LP holds 905,384 shares of ACAD stock, worth $13.4 Million. This represents 4.23% of its overall portfolio holdings.

Number of Shares

905,384

Previous 840,453 7.73%

Holding current value

$13.4 Million

Previous $15.5 Million 5.32%

% of portfolio

4.23%

Previous 4.27%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$14.62 - $18.42 $949,291 - $1.2 Million	64,931 Added 7.73%	905,384 $14.7 Million
Q1 2024 May 14, 2024	BUY	$17.79 - $30.86 $1.26 Million - $2.18 Million	70,800 Added 9.2%	840,453 $15.5 Million
Q4 2023 Feb 13, 2024	BUY	$20.78 - $31.77 $4.43 Million - $6.77 Million	213,100 Added 38.29%	769,653 $24.1 Million
Q3 2023 Nov 13, 2023	SELL	$20.84 - $33.47 $6.05 Million - $9.72 Million	-290,400 Reduced 34.29%	556,553 $11.6 Million
Q2 2023 Aug 11, 2023	SELL	$17.8 - $25.65 $1.24 Million - $1.78 Million	-69,400 Reduced 7.57%	846,953 $20.3 Million
Q1 2023 May 12, 2023	SELL	$16.32 - $20.92 $4.25 Million - $5.45 Million	-260,477 Reduced 22.13%	916,353 $17.2 Million
Q4 2022 Feb 13, 2023	BUY	$14.2 - $18.63 $934,360 - $1.23 Million	65,800 Added 5.92%	1,176,830 $18.7 Million
Q3 2022 Nov 10, 2022	BUY	$14.11 - $18.27 $5.7 Million - $7.38 Million	403,830 Added 57.1%	1,111,030 $18.2 Million
Q2 2022 Aug 12, 2022	BUY	$13.01 - $27.22 $9.2 Million - $19.2 Million	707,200 New	707,200 $9.96 Million

Others Institutions Holding ACAD

# of Institutions

288

Shares Held

161M

Call Options Held

723K

Put Options Held

257K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.39B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Finepoint Capital LP with notifications on news.

Account

Finepoint Capital LP Acadia Pharmaceuticals Inc Transaction History